Immuron Business Summary

Immuron Ltd (IMRN) is a commercial-stage biopharmaceutical company that generates revenue through the sale of orally delivered, hyper-immune bovine colostrum-based polyclonal antibodies. The company operates through two primary business segments: Hyper-immune Products, which drives immediate cash flow via over-the-counter (OTC) brands such as Travelan (travelers' diarrhea prevention), Protectyn (digestive health), and the newly launched ProIBS (irritable bowel syndrome); and Research and Development, which focuses on clinical-stage candidates like IMM-529 for C. difficile and IMM-124E for enteric pathogens. Immuron competes directly with other ASX and Nasdaq-listed biotechs such as Immutep Ltd, Imugene Ltd, and Dimerix Ltd. Within this landscape, Immuron distinguishes itself by leveraging a non-GMO, dairy-derived platform that offers a streamlined regulatory path to market compared to traditional synthetic drug developers. The leadership team is headed by CEO Steven Lydeamore, who joined in 2022 with a background in transitioning biotech firms from preclinical to clinical stages, notably at Anatara Lifesciences. In February 2026, the company strengthened its financial oversight by appointing Aaron Laurita as Chief Financial Officer and Olga Smejkalova as Company Secretary. The scientific direction is led by Chief Scientific Officer Dr. Jerry Kanellos, a 30-year industry veteran, while commercial strategy is managed by Chief Commercial Officer Flavio Palumbo. The board is chaired by Paul Brennan, the former CEO of PolyNovo who famously oversaw its market cap growth from $30 million to $2 billion. Other notable board members include Dr. Jeannie Joughin and Richard Jay Berman, providing the company with deep expertise in global clinical development and venture capital.